BioInvent International AB (publ) (LON:0H22)
London flag London · Delayed Price · Currency is GBP · Price in SEK
22.83
-0.43 (-1.83%)
At close: Mar 6, 2026

Revenue by Segment

Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16
Develops Antibody-Based Drugs
226.50M44.69M71.46M326.13M19.38M
Develops Antibody-Based Drugs Growth
406.86%-37.47%-78.09%1582.45%-86.85%
Total
226.50M44.69M71.46M326.13M19.38M
Total Growth
406.86%-37.47%-78.09%1582.45%-86.85%

Revenue by Geography

Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16
Sweden
13.72M3.89M18.26M25.63M13.52M
Sweden Growth
253.05%-78.72%-28.75%89.67%391.99%
Europe
1.24M2.93M2.95M27.10M4.21M
Europe Growth
-57.69%-0.85%-89.11%543.29%-87.71%
USA
210.95M36.82M47.39M273.39M1.66M
USA Growth
472.90%-22.30%-82.66%16409.06%-98.15%
Other Countries
582.00K1.05M2.85M--
Other Countries Growth
-44.62%-63.17%---
Total
226.50M44.69M71.46M326.13M19.38M
Total Growth
406.86%-37.47%-78.09%1582.45%-86.85%
Source: S&P Global Market Intelligence.